CYP 3.92% 24.5¢ cynata therapeutics limited

Fair Value Please, page-277

  1. 35,472 Posts.
    lightbulb Created with Sketch. 2863
    Key Highlights•
    448-patient Phase 2 clinical trial in osteoarthritis expected to commence in 2H 2019

    Costs of trial substantially funded by NHMRC; no cash contribution from Cynata
    Cynata to supply Cymerus MSCs to facilitate the trial

    This trial will be one of the largest MSC trials ever run, representing a breakthrough achievement for Cynata and showcasing its capacity to produce MSCs at scale
    •Cynata retains full commercial rights to the use of Cymerus MSCs in osteoarthritis, representing a market opportunity forecast to be worth US$11.6 billion globally by 2025
    •Osteoarthritis becomes the third Phase 2 indication for Cynata, highlighting demand for the company’s Cymerus MSCs in multiple indications
    •Trial will take place in Sydney and Tasmania, and will be managed by a world-class clinical team led by Professor David Hunter of the University of Sydney
    Last edited by Sector: 12/08/19
 
watchlist Created with Sketch. Add CYP (ASX) to my watchlist
(20min delay)
Last
24.5¢
Change
-0.010(3.92%)
Mkt cap ! $44.01M
Open High Low Value Volume
25.5¢ 25.5¢ 24.5¢ $23.65K 94.55K

Buyers (Bids)

No. Vol. Price($)
1 40000 25.0¢
 

Sellers (Offers)

Price($) Vol. No.
26.0¢ 36715 1
View Market Depth
Last trade - 15.10pm 29/07/2024 (20 minute delay) ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.